Avadel Pharmaceuticals to Present at the 29th Annual Piper Jaffray Healthcare Conference
27 11월 2017 - 9:30PM
Avadel Pharmaceuticals plc (NASDAQ:AVDL), today announced that Mike
Kanan, Chief Financial Officer, and Lauren Stival, Senior Director,
Investor Relations, will participate in a fireside chat at the 29th
Annual Piper Jaffray Healthcare Conference in New York City on
Wednesday, November 29, 2017 at 8:30 a.m. EST.
A live audio webcast of the presentation can be
accessed at the Investor section of the Company’s website,
www.avadel.com. A replay of the webcast will be available on the
Company’s website for 90 days following the event.
About Avadel Pharmaceuticals
plc: Avadel Pharmaceuticals plc (NASDAQ:AVDL) is a
specialty pharmaceutical company that seeks to commercialize
differentiated pharmaceutical products that are safe, effective and
easy to take through formulation development, by utilizing its
proprietary drug delivery technology and in-licensing / acquiring
new products; ultimately, helping patients adhere to their
prescribed medical treatment and see better results. The Company is
headquartered in Dublin, Ireland with operations in St. Louis,
Missouri and Lyon, France. For more information, please visit
www.avadel.com.
Safe HarborThis press release
may include forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. The words “will,” “may,”
“believe,” “expect,” “anticipate,” “estimate,” “project” and
similar expressions, and the negatives thereof, identify
forward-looking statements, each of which speaks only as of the
date the statement is made. Although we believe that our
forward-looking statements are based on reasonable assumptions
within the bounds of our knowledge of our business and operations,
our business is subject to significant risks and as a result there
can be no assurance that actual results of our research,
development and commercialization activities and our results of
operations will not differ materially from the results contemplated
in such forward-looking statements. These risks include: (i) risks
relating to our license agreement with Serenity Pharmaceuticals,
LLC including that our internal analyses may overstate the market
opportunity in the United States for the drug desmopressin acetate
(the “Drug”) or we may not effectively exploit such market
opportunity, that significant safety or drug interaction problems
could arise with respect to the Drug, that we may not successfully
increase awareness of nocturia and the potential benefits of the
Drug, and that the need for management to focus attention on the
development and commercialization of the Drug could cause our
ongoing business operations to suffer; and (ii) the other risks,
uncertainties and contingencies described in the Company's filings
with the U.S. Securities and Exchange Commission, including our
annual report on Form 10-K for the year ended December 31, 2016, in
particular under the captions “Forward-Looking Statements” and
“Risk Factors,” including without limitation: our dependence on a
small number of products and customers for the majority of our
revenues; the possibility that our Bloxiverz®,Vazculep® and Akovaz®
products, which are not patent protected, could face substantial
competition resulting in a loss of market share or forcing us to
reduce the prices we charge for those products; the possibility
that we could fail to successfully complete the research and
development for pipeline products we are evaluating for potential
application to the FDA pursuant to our "unapproved-to-approved"
strategy, or that competitors could complete the development of
such products and apply for FDA approval of such products before
us; the possibility that our products may not reach the commercial
market or gain market acceptance; our need to invest substantial
sums in research and development in order to remain competitive;
our dependence on certain single providers for development of
several of our drug delivery platforms and products; our dependence
on a limited number of suppliers to manufacture our products and to
deliver certain raw materials used in our products; the possibility
that our competitors may develop and market technologies or
products that are more effective or safer than ours, or obtain
regulatory approval and market such technologies or products before
we do; the challenges in protecting the intellectual property
underlying our drug delivery platforms and other products; and our
dependence on key personnel to execute our business plan. Except as
may be required by law, we disclaim any obligation to publicly
update any forward-looking statements to reflect events after the
date of this press release.
Contacts:
Michael F. KananChief Financial
OfficerPhone: (636) 449-1844E-mail:
mkanan@avadel.com
Lauren StivalSr.
Director, Investor Relations and Corporate
CommunicationsPhone: (636) 449-5866Email:
lstival@avadel.com
Avadel Pharmaceuticals (NASDAQ:AVDL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Avadel Pharmaceuticals (NASDAQ:AVDL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024